The company intends to allocate the net proceeds toward working capital, specifically targeting research, clinical development, and commercialization efforts. A primary objective of this funding is to support the ongoing advancement of bempikibart, an anti-IL-7Rα antibody currently in Phase 2 trials for the treatment of alopecia areata.
Q32 Bio Launches $200 Million Stock Offering to Fund Autoimmune Research
Waltham-based Q32 Bio has initiated a $200 million public offering of common stock and pre-funded warrants, aiming to bolster its clinical pipeline. The biotechnology firm, which specializes in therapies for alopecia areata, is also granting underwriters an option to purchase an additional $30 million in shares.
Morgan Stanley, Jefferies, and Cantor are serving as joint book-running managers for the transaction. The offering is being conducted under a shelf registration statement declared effective by the SEC on July 13, 2026. Final terms and the completion of the sale remain subject to prevailing market conditions.
Comments (0)
No comments yet. Be the first!